{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T19:04:04Z","timestamp":1763924644553},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2000,5]]},"DOI":"10.1007\/s11940-000-0007-0","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T17:43:56Z","timestamp":1180979036000},"page":"243-262","source":"Crossref","is-referenced-by-count":7,"title":["Huntington\u2019s disease"],"prefix":"10.1007","volume":"2","author":[{"given":"Barbara A.","family":"Haskins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madaline B.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"7_CR1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1750-3639.1997.tb00892.x","volume":"7","author":"MA Nance","year":"1997","unstructured":"Nance MA: Clinical aspects of CAG repeat diseases. Brain Pathol 1997, 7:881\u2013900. A recent review of the clinical and genetic features of this newly recognized category of diseases.","journal-title":"Brain Pathol"},{"key":"7_CR2","first-page":"1","volume":"59","author":"MA Nance","year":"1996","unstructured":"Nance MA: Huntington disease\u2014another chapter rewritten. Am J Hum Genet 1996, 59:1\u20136.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"7_CR3","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/070674379804300909","volume":"43","author":"I Leroi","year":"1998","unstructured":"Leroi I, Michalon M: Treatment of the psychiatric manifestations of Huntington\u2019s: a review of the literature. Can J Psychiatry 1998, 43(9):933\u2013940. A recent clinically oriented review of the literature.","journal-title":"Can J Psychiatry"},{"key":"7_CR4","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1136\/jnnp.47.12.1283","volume":"47","author":"M Schoenfeld","year":"1984","unstructured":"Schoenfeld M, Myers RN, Cupples LA, et al.: Increased rate of suicide among patients with Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 1984, 47:1283\u20131287.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7_CR5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ajmg.1320240211","volume":"2","author":"LA Farrer","year":"1986","unstructured":"Farrer LA: Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet 1986, 2:305\u2013311.","journal-title":"Am J Med Genet"},{"key":"7_CR6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1086\/302374","volume":"64","author":"EW Almqvist","year":"1999","unstructured":"Almqvist EW, Block M, Brinkman R, et al.: A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet 1999, 64:1293\u20131304. Large sample size helps allay physicians\u2019 fears about patient suicide after confirmation of carrier status. Good testing protocols and screening are essential to continued success.","journal-title":"Am J Hum Genet"},{"key":"7_CR7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0193-953X(05)70352-X","volume":"20","author":"CR Savage","year":"1997","unstructured":"Savage CR: Neuropsychology of subcortical dementias. Psychiatr Clin North Am 1997, 20:991\u2013931.","journal-title":"Psychiatr Clin North Am"},{"key":"7_CR8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00005053-199303000-00008","volume":"181","author":"JC Rothlind","year":"1993","unstructured":"Rothlind JC, Bylsma FW, Peyser C, et al.: Cognitive and motor correlates of everyday functioning in early Huntington\u2019s disease. J Nerv Ment Dis 1993, 181:194\u2013199.","journal-title":"J Nerv Ment Dis"},{"key":"7_CR9","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1212\/WNL.45.10.1867","volume":"45","author":"KA Bamford","year":"1995","unstructured":"Bamford KA, Caine ED, Kido DK, et al.: A prospective evaluation of cognitive decline in early Huntington\u2019s disease: functional and radiographic correlates. Neurology 1995, 45:1867\u20131873.","journal-title":"Neurology"},{"key":"7_CR10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0959-4388(96)80024-9","volume":"6","author":"T Wichmann","year":"1996","unstructured":"Wichmann T, DeLong MR: Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 1996, 6:751\u2013758.","journal-title":"Curr Opin Neurobiol"},{"key":"7_CR11","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/brain\/116.5.1201","volume":"116","author":"E Storey","year":"1993","unstructured":"Storey E, Beal MF: Neurochemical substrates of rigidity and chorea in Huntington\u2019s disease. Brain 1993, 116:1201\u20131222.","journal-title":"Brain"},{"issue":"3","key":"7_CR12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1176\/jnp.10.3.249","volume":"10","author":"EC Lauterbach","year":"1998","unstructured":"Lauterbach EC, Cummings JL, Duffy J: Neuropsychiatric correlates and treatment of lenticulostriatal diseases. J Neuropsychiatry Clin Neurosci 1998, 10(3):249\u2013266.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"7_CR13","first-page":"41","volume-title":"A Physician\u2019s Guide to the Management of Huntington\u2019s Disease","author":"A Rosenblatt","year":"1999","unstructured":"Rosenblatt A, Ranen NG, Nance MA, Paulsen JS: A Physician\u2019s Guide to the Management of Huntington\u2019s Disease, edn 2. New York: Huntington\u2019s Disease Society of America; 1999:41. The management of Huntington\u2019s disease is reviewed by a group of experienced clinicians who address the full range of issues encountered by patients and families. Very useful sections on behavioral and environmental strategies for caregivers are included.","edition":"edn 2"},{"key":"7_CR14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp.65.4.467","volume":"65","author":"P Jenson","year":"1998","unstructured":"Jenson P, Fenge K, Bolwig TG, et al.: Crime in Huntington\u2019s disease: a study of more registered offences among patients, relatives, and controls. J Neurol Neurosurg Psychiatry 1998, 65:467\u2013471. The only systematic look in the literature at crime rates for patients with Huntington\u2019s disease.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7_CR15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.5694\/j.1326-5377.1981.tb135681.x","volume":"1","author":"PR Sanberg","year":"1981","unstructured":"Sanberg PR, Fibiger HC, Mark RF: Body weight and dietary factors in Huntington\u2019s disease patients compared with matched controls. Med J Aust 1981, 1:407\u2013409.","journal-title":"Med J Aust"},{"key":"7_CR16","first-page":"337","volume-title":"Basal Ganglia","author":"TN Chase","year":"1976","unstructured":"Chase TN: Rational approaches to the pharmacotherapy of chorea. In Basal Ganglia. Edited by Yahr MD. New York: Raven Press; 1976:337\u2013350."},{"key":"7_CR17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2165\/00003495-199652060-00006","volume":"52","author":"H Shale","year":"1996","unstructured":"Shale H, Tanner C: Pharmacological options for the management of dyskinesias. Drugs 1996, 52:849\u2013860.","journal-title":"Drugs"},{"issue":"4","key":"7_CR18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/mds.870110406","volume":"11","author":"JPP Vugt van","year":"1996","unstructured":"van Vugt JPP, van Hilten BJ, Roos RAC: Hypokinesia in Huntington\u2019s disease. Mov Disord 1996, 11(4):384\u2013388.","journal-title":"Mov Disord"},{"issue":"suppl 11","key":"7_CR19","first-page":"4","volume":"57","author":"E Richelson","year":"1996","unstructured":"Richelson E: Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996, 57(suppl 11):4\u201311.","journal-title":"J Clin Psychiatry"},{"issue":"suppl 10","key":"7_CR20","first-page":"55","volume":"58","author":"DE Casey","year":"1997","unstructured":"Casey DE: The relationship of pharmacology to side effects. J Clin Psychiatry 1997, 58(suppl 10):55\u201362.","journal-title":"J Clin Psychiatry"},{"key":"7_CR21","first-page":"57","volume":"13","author":"DC Goff","year":"1993","unstructured":"Goff DC, Baldessarini RJ: Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993, 13:57\u201367.","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl 12","key":"7_CR22","first-page":"23","volume":"59","author":"Collaborative Working Group on Clinical Trial Evaluation","year":"1998","unstructured":"Collaborative Working Group on Clinical Trial Evaluation: Assessment of EPS and tardive dyskinesia in clinical trials. J Clin Psychiatry 1998, 59(suppl 12):23\u201327.","journal-title":"J Clin Psychiatry"},{"key":"7_CR23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/026988119601000213","volume":"10","author":"MA Reveley","year":"1996","unstructured":"Reveley MA, Dursun SM, Andrews H: A comparative trial of use of sulpiride and risperidone in Huntington\u2019s disease: a pilot study. J Psychopharmacol 1996, 10:162\u2013165.","journal-title":"J Psychopharmacol"},{"key":"7_CR24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004714-199902000-00020","volume":"19","author":"C Dallocchio","year":"1999","unstructured":"Dallocchio C, Buffa C, Tinelli C, Mazzarello P: Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol 1999, 19:101\u2013103.","journal-title":"J Clin Psychopharmacol"},{"key":"7_CR25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","volume":"13","author":"G Chouinard","year":"1993","unstructured":"Chouinard G, Jones B, Remington G, et al.: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993, 13:25\u201340.","journal-title":"J Clin Psychopharmacol"},{"key":"7_CR26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mds.870120403","volume":"12","author":"SA Factor","year":"1997","unstructured":"Factor SA, Friedman JH: The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997, 12:483\u2013496.","journal-title":"Mov Disord"},{"key":"7_CR27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1212\/WNL.44.5.821","volume":"44","author":"U Bonuccelli","year":"1994","unstructured":"Bonuccelli U, Ceravolo R, Maremmani C, et al.: Clozapine in Huntington\u2019s chorea. Neurology 1994, 44:821\u2013823.","journal-title":"Neurology"},{"key":"7_CR28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jnnp.63.1.35","volume":"63","author":"JPP Vugt van","year":"1997","unstructured":"van Vugt JPP, Siesling S, Vergeer M, et al.: Clozapine versus placebo in Huntington\u2019s disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997, 63:35\u201339.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"suppl 11","key":"7_CR29","first-page":"12","volume":"57","author":"L Ereshefsky","year":"1996","unstructured":"Ereshefsky L: Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996, 57(suppl 11):12\u201325.","journal-title":"J Clin Psychiatry"},{"key":"7_CR30","first-page":"846","volume":"12","author":"D Leszczyszyn","year":"1997","unstructured":"Leszczyszyn D, Nohria V, Anderson S: Sustained improvement of juvenile Huntington disease with levodopa\/carbidopa [abstract]. Mov Disord 1997, 12:846.","journal-title":"Mov Disord"},{"key":"7_CR31","first-page":"557","volume":"64","author":"BA Racette","year":"1998","unstructured":"Racette BA, Perlmutter JS: Levodopa responsive parkinsonism in an adult with Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 1998, 64:557\u2013579.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7_CR32","first-page":"168","volume":"41","author":"SE Folstein","year":"1987","unstructured":"Folstein SE, Chase GA, Wahl WE, et al.: Huntington\u2019s disease in Maryland: clinical aspects of racial variation. Am J Hum Genet 1987, 41:168\u2013179.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"7_CR33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00005053-199001000-00004","volume":"178","author":"A Burns","year":"1999","unstructured":"Burns A, Folstein S, Brandt J, et al.: Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease. J Nerv Ment Dis 1999, 178(1):20\u201326.","journal-title":"J Nerv Ment Dis"},{"issue":"3","key":"7_CR34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2190\/HU6W-3K7Q-NAEL-XU6K","volume":"24","author":"MF Mendez","year":"1994","unstructured":"Mendez MF: Huntington\u2019s disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med 1994, 24(3):189\u2013208.","journal-title":"Int J Psychiatry Med"},{"issue":"2","key":"7_CR35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0987-7053(96)81034-3","volume":"25","author":"R Silvestri","year":"1995","unstructured":"Silvestri R, Raffaele M, De Domenico P, et al.: Sleep features in Tourette\u2019s syndrome, neuroacanthocytosis and Huntington\u2019s chorea. Neurophysiol Clin 1995, 25(2):66\u201377.","journal-title":"Neurophysiol Clin"},{"issue":"suppl 1","key":"7_CR36","first-page":"1","volume":"17","author":"MS Aldrich","year":"1993","unstructured":"Aldrich MS: Insomnia in neurological diseases. J Psychosom Res 1993, 17(suppl 1):1\u201311.","journal-title":"J Psychosom Res"},{"key":"7_CR37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1192\/bjp.171.4.393c","volume":"171","author":"N Taylor","year":"1997","unstructured":"Taylor N, Bramble D: Sleep disturbance and Huntington\u2019s disease [letter]. Br J Psychiatry 1997, 171:393.","journal-title":"Br J Psychiatry"},{"key":"7_CR38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1176\/jnp.6.2.147","volume":"6","author":"JP Fedoroff","year":"1994","unstructured":"Fedoroff JP, Peyser C, Franz ML, et al.: Sexual disorders in Huntington\u2019s disease. J Neuropsychiatry 1994, 6:147\u2013153.","journal-title":"J Neuropsychiatry"},{"issue":"3","key":"7_CR39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/mds.870090317","volume":"9","author":"SS Rich","year":"1994","unstructured":"Rich SS, Ovsiew F: Leuprolide acetate for exhibitionism in Huntington\u2019s disease. Mov Disord 1994, 9(3):353\u2013357.","journal-title":"Mov Disord"},{"issue":"2","key":"7_CR40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1176\/jnp.6.2.154","volume":"6","author":"NG Ranen","year":"1994","unstructured":"Ranen NG, Peyser CE, Folstein SE: ECT as a treatment for depression in Huntington\u2019s disease. J Neuropsychiatry 1994, 6(2):154\u2013159.","journal-title":"J Neuropsychiatry"},{"key":"7_CR41","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1212\/WNL.44.8.1533","volume":"44","author":"International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington\u2019s Chorea","year":"1994","unstructured":"International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington\u2019s Chorea: Guidelines for the molecular genetics predictive test in Huntington\u2019s disease. Neurology 1994, 44:1533\u20131536.","journal-title":"Neurology"},{"key":"7_CR42","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1212\/WNL.44.8.1369","volume":"44","author":"S Hersch","year":"1994","unstructured":"Hersch S, Jones R, Koroshetz W, Quaid K: The neurogenetics genie: testing for the Huntington\u2019s disease mutation. Neurology 1994, 44:1369\u20131373. Discussion of the recommended protocol for genetic testing in Huntington\u2019s disease. Outlines the rationale and reviews the issues that should be considered by all clinicians recommending such testing.","journal-title":"Neurology"},{"key":"7_CR43","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1086\/301846","volume":"62","author":"The American College of Medical Genetics\/American Society of Human Genetics Huntington Disease Genetic Testing Working Group","year":"1998","unstructured":"The American College of Medical Genetics\/American Society of Human Genetics Huntington Disease Genetic Testing Working Group: Laboratory guidelines for Huntington disease genetic testing. Am J Hum Genet 1998, 62:1243\u20131247.","journal-title":"Am J Hum Genet"},{"key":"7_CR44","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00019052-199808000-00012","volume":"11","author":"A Feigin","year":"1998","unstructured":"Feigin A: Advances in Huntington\u2019s disease: implications for experimental therapeutics. Curr Opin Neurol 1998, 11:357\u2013362. Review of the clinical implications of recent basic science advances in understanding the molecular pathology of Huntington\u2019s disease.","journal-title":"Curr Opin Neurol"},{"key":"7_CR45","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q","volume":"14","author":"HD Rosas","year":"1999","unstructured":"Rosas HD, Koroshetz WJ, Jenkins BG, et al.: Riluzole therapy in Huntington\u2019s disease (HD). Mov Disord 1999, 14:326\u2013330.","journal-title":"Mov Disord"},{"key":"7_CR46","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mds.870110310","volume":"11","author":"K Kieburtz","year":"1996","unstructured":"Kieburtz K, Feigin A, McDermott M, et al.: A controlled trial of remacemide hydrochloride in Huntington\u2019s disease. Mov Disord 1996, 11:273\u2013277.","journal-title":"Mov Disord"},{"key":"7_CR47","first-page":"97","volume":"55","author":"K Kieburtz","year":"1999","unstructured":"Kieburtz K: Antiglutamate therapies in Huntington\u2019s disease. J Neural Transm Suppl 1999, 55:97\u2013102.","journal-title":"J Neural Transm Suppl"},{"key":"7_CR48","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.410410206","volume":"41","author":"WJ Koroshetz","year":"1997","unstructured":"Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF: Energy metabolism defects in Huntington\u2019s disease and effects of coenzyme Q10. Ann Neurol 1997, 41:160\u2013165.","journal-title":"Ann Neurol"},{"key":"7_CR49","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1176\/ajp.152.12.1771","volume":"152","author":"CE Peyser","year":"1995","unstructured":"Peyser CE, Folstein M, Chase GA, et al.: Trial of d-alphatocopherol in Huntington\u2019s disease. Am J Psychiatry 1995, 152:1771\u20131775.","journal-title":"Am J Psychiatry"},{"key":"7_CR50","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mds.870110510","volume":"11","author":"NG Ranen","year":"1996","unstructured":"Ranen NG, Peyser CE, Coyle JT, et al.: A controlled trial of idebenone in Huntington\u2019s disease. Mov Disord 1996, 11:549\u2013554.","journal-title":"Mov Disord"},{"key":"7_CR51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/096368979600500222","volume":"5","author":"KM Shannon","year":"1996","unstructured":"Shannon KM, Kordower JH: Neural transplantation for Huntington\u2019s disease: experimental rationale and recommendations for clinical trials. Cell Transplant 1996, 5:339\u2013352.","journal-title":"Cell Transplant"},{"key":"7_CR52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/exnr.1997.6685","volume":"149","author":"OV Kopyov","year":"1998","unstructured":"Kopyov OV, Jacques S, Lieberman A, et al.: Safety of intrastriatal neurotransplantation for Huntington\u2019s disease patients. Exp Neurol 1998, 149:97\u2013108.","journal-title":"Exp Neurol"},{"key":"7_CR53","unstructured":"University of Kansas Department of Neurology Huntington\u2019s disease Web page: http:\/\/www.kumc.edu\/ hospital\/huntingtons\/HSGFTrans.html."},{"key":"7_CR54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/mds.870110202","volume":"11","author":"N Quinn","year":"1996","unstructured":"Quinn N, Brown R, Craufurd D, et al.: Core Assessment Program for Intracerebral Transplantation in Huntington\u2019s Disease (CAPIT-HD). Mov Disord 1996, 11:143\u2013150.","journal-title":"Mov Disord"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-000-0007-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-000-0007-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-000-0007-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T18:27:46Z","timestamp":1587580066000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-000-0007-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["7"],"URL":"https:\/\/doi.org\/10.1007\/s11940-000-0007-0","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}